Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum
Authors:
- Kansai Myeloma Forum InvestigatorsKIKansai Myeloma Forum Investigators
- Junya KurodaJKJunya Kuroda
- 29 January 2018
- journal article
- research article
- Published by Springer Nature in International Journal of Hematology
- Vol. 107 (5) , 541-550
Abstract
Determinants of the efficacy and safety of pomalidomide (POM) monotherapy or POM plus dexamethasone (DEX) (POM/DEX) for relapsed and refractory multiple myeloma (RRMM) were examined retrospectively in a real-world clinical practice setting in Japan. The subjects were 108 patients registered with the Kansai Myeloma Forum, who were treated with either POM or POM/DEX. Of these, 79 (73%), 73 (68%), and 58 (54%) were resistant to bortezomib (BTZ), lenalidomide (LEN), and both BTZ and LEN, respectively. The median overall survival (OS) was not reached. The median time to treatment failure (TTF) was 4.4 months. The best response was recorded in 96 patients, with a 31% overall response rate (ORR) and a 79% rate of achieving at least stable disease. Number of pre-POM regimens ≥ 5, non-IgG-type M-protein, and time from initial therapy to POM or POM/DEX therapy < 2 years were associated with shorter TTF and OS. Frequent (> 10%) severe adverse events included neutropenia (55.1%), thrombocytopenia (33.7%), anemia (30.6%), febrile neutropenia (12.2%), fatigue (11.2%), and anorexia (10.2%). In conclusion, POM and POM/DEX showed substantial efficacy against RRMM, but new combination therapies with POM are needed to improve efficacy further without causing hematologic toxicities.Keywords
Funding Information
- Celgene Co., Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Fujimoto Pharmaceutical Co. Ltd.
- Ono Pharmaceutical Co., Ltd.
This publication has 35 references indexed in Scilit:
- Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myelomaInternational Journal of Hematology, 2014
- Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agentsInternational Journal of Hematology, 2014
- Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBNBritish Journal of Haematology, 2013
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2013
- Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02Blood, 2013
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Practical management of adverse events in multiple myeloma: Can therapy be attenuated in older patients?Blood Reviews, 2011
- Prevention of thalidomide- and lenalidomide-associated thrombosis in myelomaLeukemia, 2007
- International uniform response criteria for multiple myelomaLeukemia, 2006
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005